JCP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Journal of Clinical Pathology 2006;59:557-563; doi:10.1136/jcp.2005.031112
Copyright © 2006 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tornillo, L
Right arrow Articles by Terracciano, L M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tornillo, L
Right arrow Articles by Terracciano, L M

REVIEW

An update on molecular genetics of gastrointestinal stromal tumours

L Tornillo, L M Terracciano

Institute of Pathology, University of Basel, Basel, Switzerland

Correspondence to:
Dr Luigi Tornillo
Institute of Pathology, University of Basel, Schönbeinstrasse 40, CH-4003 Basel, Switzerland; tornillol{at}uhbs.ch
ABSTRACT
Gastrointestinal stromal tumours (GISTs) are the most common primary mesenchymal tumours of the gastrointestinal tract. Most of them show activating mutations of the genes coding for KIT or platelet-derived growth factor receptor {alpha} (PDGFR{alpha}), two receptor tyrosine kinases (RTKs). The RTK inhibitor Imatinib (Gleevec®, Novartis, Switzerland), induces regression of the tumour. The level of response to treatment, together with other clinicopathological parameters is related to the type and site of the activating mutation, thus suggesting that these tumours should be classified according to the molecular context. This is confirmed also by the phenomenon of the resistance to treatment, which arises because of different mechanisms (second mutation, amplification, activation of other RTKs) and can be fought only by specific RTK inhibitors, that are at present under development. RTK activation involves an homogeneous transduction pathway whose components (MAPK, AKT, PI3K, mTOR and RAS) are possible targets of new molecular treatment. A new paradigm of classification integrating the classic pathological criteria with the molecular changes will permit personalised prognosis and treatment.


Abbreviations: GIST, gastrointestinal stromal tumours; ICC, interstitial cells of Cajal; PDGFR, Platelet-derived growth factor receptor; PI3K, phosphatidylinositol-3-kinase; RTK, receptor tyrosine kinases




This article has been cited by other articles:


Home page
Ann OncolHome page
C. Braconi, R. Bracci, I. Bearzi, F. Bianchi, A. Costagliola, R. Catalani, A. Mandolesi, R. Ranaldi, E. Galizia, S. Cascinu, et al.
KIT and PDGFR{alpha} mutations in 104 patients with gastrointestinal stromal tumors (GISTs): a population-based study
Ann. Onc., April 1, 2008; 19(4): 706 - 710.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
A L Gomes, A Gouveia, A F Capelinha, D de la Cruz, P Silva, R M Reis, A Pimenta, and J M Lopes
Molecular alterations of KIT and PDGFRA in GISTs: evaluation of a Portuguese series
J. Clin. Pathol., February 1, 2008; 61(2): 203 - 208.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
F.=C> Miselli, P. Casieri, T. Negri, M. Orsenigo, M. S. Lagonigro, A. Gronchi, M. Fiore, P. G. Casali, R. Bertulli, A. Carbone, et al.
c-Kit/PDGFRA Gene Status Alterations Possibly Related to Primary Imatinib Resistance in Gastrointestinal Stromal Tumors
Clin. Cancer Res., April 15, 2007; 13(8): 2369 - 2377.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Journal of Clinical Pathology Molecular Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2006 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.